Clinical Trials Directory

Trials / Unknown

UnknownNCT06214117

Comparison of Emergence Delirium: Remimazolam vs Sevoflurane Anesthesia

Comparison of Emergence Agitation in Children Following Tonsillectomy and Adenoidectomy Under Remimazolam or Sevoflurane General Anesthesia

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
Second Affiliated Hospital of Wenzhou Medical University · Academic / Other
Sex
All
Age
3 Years – 6 Years
Healthy volunteers
Not accepted

Summary

Emergence delirium can lead to a range of clinical problems and is even associated with short-term behavioral changes in children. Pediatric ear, nose, and throat (ENT) surgery is one of the most common surgical types for postoperative delirium in children. Sevoflurane anesthesia is also a known cause of postoperative delirium. Therefore, this study aims to explore whether there is a difference in the incidence of postoperative delirium in children under remimazolam general anesthesia and sevoflurane anesthesia.

Detailed description

children aged 3-6 years old were randomly and equally allocated into two groups: Group R remimazolam, Group S with sevoflurane, respectively.

Conditions

Interventions

TypeNameDescription
DRUGRemimazolamAnesthesia induction:intravenous Fentanyl 2-3 μg/kg, remimazolam 0.3-0.5 mg/kg and Rocuronium 0.6mg/kg; Maintenance of anesthesia:Remimazolam will infuse initially at a rate of 2 mg/kg/h (1-3 mg/kg/h), and remifentanil will administer at an initial infusion rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
DRUGSevofluraneAnesthesia induction: Anesthesia will induce with 8% sevoflurane in 100% oxygen at flow rate of 6 L/min, and then intravenous fentanyl (2-3 μg/kg) and rocuronium (0.6 mg/kg); Maintenance of anaesthesia: Anesthesia depth will maintain at 1-1.5 minimum alveolar concentration (MAC), and remifentanil was infuse at an initial rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).

Timeline

Start date
2024-02-01
Primary completion
2025-02-01
Completion
2025-03-01
First posted
2024-01-19
Last updated
2024-01-19

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06214117. Inclusion in this directory is not an endorsement.